Vidofludimus

An immunosuppressive drug used in the treatment of autoimmune diseases

Vidofludimus is an immunosuppressive drug that is primarily used in the treatment of various autoimmune diseases. It functions by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), which is crucial in the pyrimidine biosynthesis pathway. This inhibition leads to a reduction in the proliferation of lymphocytes, which are key players in the immune response.

Mechanism of Action

Vidofludimus exerts its effects by targeting the DHODH enzyme, which is involved in the de novo synthesis of pyrimidines. By inhibiting this enzyme, vidofludimus effectively reduces the availability of pyrimidines, which are necessary for the synthesis of DNA and RNA. This action is particularly impactful on rapidly dividing cells, such as activated T cells and B cells, thereby suppressing the immune response.

Clinical Uses

Vidofludimus is used in the management of several autoimmune conditions, including:

• Rheumatoid arthritis
• Inflammatory bowel disease
• Multiple sclerosis

The drug is often considered when patients do not respond adequately to first-line treatments or when they experience significant side effects from other therapies.

Pharmacokinetics

Vidofludimus is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The drug has a relatively long half-life, allowing for once-daily dosing in most therapeutic regimens.

Side Effects

Common side effects of vidofludimus include:

• Nausea
• Diarrhea
• Headache
• Elevated liver enzymes

Patients on vidofludimus require regular monitoring of liver function tests due to the potential for hepatotoxicity.

Development and Approval

Vidofludimus was developed as part of ongoing research into DHODH inhibitors, which have shown promise in modulating the immune system. The drug has undergone various clinical trials to establish its efficacy and safety profile in different autoimmune conditions.

Research

Ongoing research is exploring the potential of vidofludimus in other autoimmune and inflammatory conditions. Studies are also investigating its use in combination with other immunosuppressive agents to enhance therapeutic outcomes.

Related Pages

• Immunosuppressive drug
• Autoimmune disease
• Dihydroorotate dehydrogenase
• Pyrimidine

Chemical structure of Vidofludimus